Pharma companies are accelerating investment in AI infrastructure and reasoning workflows designed to connect large integrated datasets (genomics to metabolomics) into end-to-end drug discovery pipelines. Coverage cited Isomorphic Labs’ $2.1 billion funding round and partnerships with Novartis, Eli Lilly, and Johnson & Johnson aimed at embedding AI-driven design workflows into mainstream R&D. Separately, commentary emphasized that healthcare organizations are deploying AI tools without operational readiness for AI agents that will work across routine clinical workflows. The gap is often tied to governance, monitoring, and the ability to manage tool behavior in real-world settings. The dual message for biotech leaders: model capability is advancing, but adoption hinges on integration discipline, data quality, and risk controls as AI moves closer to patient-facing decisions.